GlassScriptPhysician profile
Robert R Peabody
NPI 1801802095
$908.53
in general payments reported to CMS, 2019-2025
15 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.49 · 2020: $32.96 · 2021: $122 · 2022: $84.17 · 2023: $51.56 · 2024: $111 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $595.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $406.00 | 2024-2025 | Intracept, General - Pain Management |
| Alcon Vision LLC | $79.16 | 2019-2025 | Rocklatan |
| Allergan, INC. | $67.02 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $65.58 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $43.37 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $39.62 | 2020-2025 | |
| Thea Pharma INC. | $37.06 | 2023 | Iyuzeh |
| Biotissue Holdings INC. | $26.75 | 2022 | |
| Abbvie INC. | $26.02 | 2025 | |
| Carl Zeiss Meditec USA, INC. | $24.79 | 2024 | Cirrus Hd-Oct |
| Eyevance Pharmaceuticals LLC | $23.99 | 2019 | |
| Glaukos Corporation | $21.32 | 2024 | Idose |
| Kala Pharmaceuticals, INC. | $19.59 | 2021 | |
| Bausch & Lomb Americas INC. | $14.50 | 2023 | Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Peabody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.